Quince Therapeutics (QNCX) Interest & Investment Income (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Interest & Investment Income of $160000.0 for Q1 2026, down 60.59% year-over-year from $406000.0 in Q1 2025, and down 29.52% quarter-over-quarter from $227000.0 in Q4 2025.
Quince Therapeutics (QNCX) Interest & Investment Income (2018 - 2026) Analysis & Trends
Quince Therapeutics' Interest & Investment Income history runs 9 years deep, the most recent figure standing at $160000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 60.59% year-over-year to $160000.0; the TTM figure through Mar 2026 stood at $998000.0 (down 59.23% YoY), while the FY2025 annual figure was $1.2 million, down 57.53% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $160000.0, down from $227000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $1.0 million in Q4 2023, with the low at $72000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $536000.0 (2022), against an average of $522294.1.
- The sharpest annual moves came in 2022 and 2023: Interest & Investment Income tumbled 68.28% in 2022, then surged 872.22% in 2023.
- Quince Therapeutics' Interest & Investment Income stood at $536000.0 in 2022, then jumped by 89.18% to $1.0 million in 2023, then tumbled by 47.14% to $536000.0 in 2024, then tumbled by 57.65% to $227000.0 in 2025, then dropped by 29.52% to $160000.0 in 2026.
- Business Quant data shows QNCX's Interest & Investment Income at $160000.0 in Q1 2026, $227000.0 in Q4 2025, and $300000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | 584,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 160,000.00 |
| Dec 31, 2025 | 227,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 311,000.00 |
| Mar 31, 2025 | 406,000.00 |
| Dec 31, 2024 | 536,000.00 |
| Sep 30, 2024 | 683,000.00 |
| Jun 30, 2024 | 823,000.00 |
| Mar 31, 2024 | 887,000.00 |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 959,000.00 |
| Jun 30, 2023 | 805,000.00 |
| Mar 31, 2023 | 700,000.00 |
| Dec 31, 2022 | 536,000.00 |
| Sep 30, 2022 | 315,000.00 |
| Jun 30, 2022 | 145,000.00 |
| Mar 31, 2022 | 72,000.00 |
| Dec 31, 2021 | 105,000.00 |
| Sep 30, 2021 | 128,000.00 |
| Jun 30, 2021 | 160,000.00 |